355 related articles for article (PubMed ID: 18273760)
1. [Cost-effectiveness evaluation of predictive molecular diagnostics using the example of hereditary non-polyposis colorectal cancer (HNPCC)].
Hagen A; Hessabi HK; Gorenoi V; Schönermark MP
Gesundheitswesen; 2008 Jan; 70(1):18-27. PubMed ID: 18273760
[TBL] [Abstract][Full Text] [Related]
2. The relevance of unrelated costs internal and external to the healthcare sector to the outcome of a cost-comparison analysis of secondary prevention: the case of general colorectal cancer screening in the German population.
Tscheulin DK; Drevs F
Eur J Health Econ; 2010 Apr; 11(2):141-50. PubMed ID: 19449159
[TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness of surveillance programs for families at high and moderate risk of hereditary non-polyposis colorectal cancer.
Olsen KR; Bojesen SE; Gerdes AM; Lindorff-Larsen K; Bernstein IT
Int J Technol Assess Health Care; 2007; 23(1):89-95. PubMed ID: 17234021
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness analysis on screening for colorectal neoplasm and management of colorectal cancer in Asia.
Tsoi KK; Ng SS; Leung MC; Sung JJ
Aliment Pharmacol Ther; 2008 Aug; 28(3):353-63. PubMed ID: 18638075
[TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness of screening for colorectal cancer in France using a guaiac test versus an immunochemical test.
Lejeune C; Dancourt V; Arveux P; Bonithon-Kopp C; Faivre J
Int J Technol Assess Health Care; 2010 Jan; 26(1):40-7. PubMed ID: 20059779
[TBL] [Abstract][Full Text] [Related]
6. Cost-effectiveness of colorectal cancer screening in renal transplant recipients.
Wong G; Howard K; Craig JC; Chapman JR
Transplantation; 2008 Feb; 85(4):532-41. PubMed ID: 18347531
[TBL] [Abstract][Full Text] [Related]
7. Cost effectiveness of a new strategy to identify HNPCC patients.
Kievit W; de Bruin JH; Adang EM; Severens JL; Kleibeuker JH; Sijmons RH; Ruers TJ; Nagengast FM; Vasen HF; van Krieken JH; Ligtenberg MJ; Hoogerbrugge N
Gut; 2005 Jan; 54(1):97-102. PubMed ID: 15591512
[TBL] [Abstract][Full Text] [Related]
8. High participation rates are not necessary for cost-effective colorectal cancer screening.
Howard K; Salkeld G; Irwig L; Adelstein BA
J Med Screen; 2005; 12(2):96-102. PubMed ID: 15949121
[TBL] [Abstract][Full Text] [Related]
9. [Juvenile obesity and comorbidity type 2 diabetes mellitus (T2 DM) in Germany: development and cost-of-illness analysis].
Wolfenstetter SB
Gesundheitswesen; 2006 Oct; 68(10):600-12. PubMed ID: 17099820
[TBL] [Abstract][Full Text] [Related]
10. The cost-effectiveness of routine office-based identification and subsequent medical treatment of primary open-angle glaucoma in the United States.
Rein DB; Wittenborn JS; Lee PP; Wirth KE; Sorensen SW; Hoerger TJ; Saaddine JB
Ophthalmology; 2009 May; 116(5):823-32. PubMed ID: 19285730
[TBL] [Abstract][Full Text] [Related]
11. Cost-effectiveness analysis in colorectal cancer using a semi-Markov model.
Castelli C; Combescure C; Foucher Y; Daures JP
Stat Med; 2007 Dec; 26(30):5557-71. PubMed ID: 18058847
[TBL] [Abstract][Full Text] [Related]
12. Cost-effectiveness analysis of the genetic screening program for familial hypercholesterolemia in The Netherlands.
Wonderling D; Umans-Eckenhausen MA; Marks D; Defesche JC; Kastelein JJ; Thorogood M
Semin Vasc Med; 2004 Feb; 4(1):97-104. PubMed ID: 15199439
[TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness of human papillomavirus vaccination in Belgium: do not forget about cervical cancer screening.
Thiry N; De Laet C; Hulstaert F; Neyt M; Huybrechts M; Cleemput I
Int J Technol Assess Health Care; 2009 Apr; 25(2):161-70. PubMed ID: 19366497
[TBL] [Abstract][Full Text] [Related]
14. Cost-effectiveness analysis in the clinical management of patients with known or suspected lung cancer: [18F]fluorodeoxyglucose PET and CT comparison.
Mansueto M; Grimaldi A; Torbica A; Pepe G; Giovacchini G; Messa C; Fazio F
Q J Nucl Med Mol Imaging; 2007 Sep; 51(3):224-34. PubMed ID: 17538525
[TBL] [Abstract][Full Text] [Related]
15. Costs and cost effectiveness of a health care provider-directed intervention to promote colorectal cancer screening among Veterans.
Wolf MS; Fitzner KA; Powell EF; McCaffrey KR; Pickard AS; McKoy JM; Lindenberg J; Schumock GT; Carson KR; Ferreira MR; Dolan NC; Bennett CL
J Clin Oncol; 2005 Dec; 23(34):8877-83. PubMed ID: 16314648
[TBL] [Abstract][Full Text] [Related]
16. Should female relatives of factor V Leiden carriers be screened prior to oral contraceptive use? A cost-effectiveness analysis.
Smith KJ; Monsef BS; Ragni MV
Thromb Haemost; 2008 Sep; 100(3):447-52. PubMed ID: 18766261
[TBL] [Abstract][Full Text] [Related]
17. Cost-effectiveness analysis for determining optimal cut-off of immunochemical faecal occult blood test for population-based colorectal cancer screening (KCIS 16).
Chen LS; Liao CS; Chang SH; Lai HC; Chen TH
J Med Screen; 2007; 14(4):191-9. PubMed ID: 18078564
[TBL] [Abstract][Full Text] [Related]
18. Evaluating adolescents in juvenile detention facilities for urogenital chlamydial infection: costs and effectiveness of alternative interventions.
Mrus JM; Biro FM; Huang B; Tsevat J
Arch Pediatr Adolesc Med; 2003 Jul; 157(7):696-702. PubMed ID: 12860793
[TBL] [Abstract][Full Text] [Related]
19. Colon cancer prevention in Italy: cost-effectiveness analysis with CT colonography and endoscopy.
Hassan C; Zullo A; Laghi A; Reitano I; Taggi F; Cerro P; Iafrate F; Giustini M; Winn S; Morini S
Dig Liver Dis; 2007 Mar; 39(3):242-50. PubMed ID: 17112797
[TBL] [Abstract][Full Text] [Related]
20. Testing for occult cancer in patients with idiopathic deep vein thrombosis--a decision analysis.
Barosi G; Marchetti M; Dazzi L; Quaglini S
Thromb Haemost; 1997 Nov; 78(5):1319-26. PubMed ID: 9408012
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
